Iovance Biotherapeutics (Iovance Biotherapeutics) Market Cap : $2,999.80 Mil (As of May. 14, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Iovance Biotherapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Iovance Biotherapeutics's share price for the quarter that ended in Mar. 2024 was $14.82. Iovance Biotherapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 279.76 Mil. Therefore, Iovance Biotherapeutics's market cap for the quarter that ended in Mar. 2024 was $4,145.98 Mil.

Iovance Biotherapeutics's quarterly market cap increased from Sep. 2023 ($1,164.04 Mil) to Dec. 2023 ($2,082.39 Mil) and increased from Dec. 2023 ($2,082.39 Mil) to Mar. 2024 ($4,145.98 Mil).

Iovance Biotherapeutics's annual market cap declined from Dec. 2021 ($2,997.23 Mil) to Dec. 2022 ($1,200.12 Mil) but then increased from Dec. 2022 ($1,200.12 Mil) to Dec. 2023 ($2,082.39 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Iovance Biotherapeutics's Enterprise Value for Today is $2,772.76 Mil.

Iovance Biotherapeutics Market Cap Historical Data

The historical data trend for Iovance Biotherapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics Market Cap Chart

Iovance Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

3,499.08

6,815.00

2,997.23

1,200.12

2,082.39

Iovance Biotherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Market Cap	Get a 7-Day Free Trial															1,370.83	1,581.80	1,164.04	2,082.39	4,145.98

Competitive Comparison of Iovance Biotherapeutics's Market Cap

For the Biotechnology subindustry, Iovance Biotherapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iovance Biotherapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Market Cap falls into.

Iovance Biotherapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Iovance Biotherapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$8.13	*	256.136
	=	$2,082.39

Iovance Biotherapeutics's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )	=	Share Price (Q: Mar. 2024 )	*	Shares Outstanding (EOP) (Q: Mar. 2024 )
	=	$14.82	*	279.756
	=	$4,145.98

Iovance Biotherapeutics (NAS:IOVA) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Iovance Biotherapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics (Iovance Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (NAS:IOVA) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

2LB:Germany 2LB:Germany

Address

825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Executives

Merrill A Mcpeak	director	PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001
Wayne P. Rothbaum	director	C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019
Wendy L Yarno	director
Frederick G Vogt	officer: General Counsel	2120 HEMLOCK RD., WEST NORRITON PA 19403
Iain D. Dukes	director	112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Wendy L Dixon	director
Ryan D Maynard	director	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Michael Weiser	director	C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Igor Bilinsky	officer: Chief Operating Officer	C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jean-marc Bellemin	officer: Chief Financial Officer	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Michael Swartzburg	officer: VP, Finance	C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Athena Countouriotis	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Finckenstein Friedrich Graf	officer: Chief Medical Officer	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Timothy E Morris	officer: Chief Financial Officer	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Maria Fardis	director, officer: President and CEO	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085